KLAC vs. ABBV
KLAC (KLA Corporation) and ABBV (AbbVie Inc.) are both stocks. KLAC operates in Semiconductor Equipment & Materials (Technology), while ABBV operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, KLAC returned 45.08%/yr vs 19.10%/yr for ABBV. At a 0.23 correlation, their price movements are largely independent.
Performance
KLAC vs. ABBV - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, KLAC achieves a 110.02% return, which is significantly higher than ABBV's 1.30% return. Over the past 10 years, KLAC has outperformed ABBV with an annualized return of 45.08%, while ABBV has yielded a comparatively lower 19.10% annualized return.
KLAC
- 1D
- 5.55%
- 1M
- 37.79%
- YTD
- 110.02%
- 6M
- 113.75%
- 1Y
- 192.78%
- 3Y*
- 75.88%
- 5Y*
- 52.93%
- 10Y*
- 45.08%
ABBV
- 1D
- 1.32%
- 1M
- 9.22%
- YTD
- 1.30%
- 6M
- 3.65%
- 1Y
- 22.21%
- 3Y*
- 22.39%
- 5Y*
- 18.94%
- 10Y*
- 19.10%
KLAC vs. ABBV - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
KLAC KLA Corporation | 110.02% | 94.48% | 9.36% | 56.05% | -11.20% | 68.05% | 47.94% | 103.99% | -12.49% | 36.80% |
ABBV AbbVie Inc. | 1.30% | 33.08% | 18.86% | -0.23% | 24.01% | 32.43% | 27.72% | 1.47% | -0.96% | 60.07% |
Correlation
The correlation between KLAC and ABBV is -0.02, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.02 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.06 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.09 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.19 |
Correlation (All Time) Calculated using the full available price history since Jan 2, 2013 | 0.23 |
The correlation between KLAC and ABBV shifts across timeframes, from -0.02 (1 year) to 0.23 (all time), reflecting how their relationship changes across market environments.
Fundamentals
KLAC:
$33.62B
ABBV:
$403.99B
KLAC:
$35.29
ABBV:
$2.05
KLAC:
7.21
ABBV:
110.96
KLAC:
2.57
ABBV:
6.43
KLAC:
5.77
ABBV:
14.69
KLAC:
$13.10B
ABBV:
$62.82B
KLAC:
$8.09B
ABBV:
$46.15B
KLAC:
$5.77B
ABBV:
$17.96B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KLAC vs. ABBV — Risk / Return Rank
KLAC
ABBV
KLAC vs. ABBV - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for KLA Corporation (KLAC) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| KLAC | ABBV | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +3.01 | ||
| Sortino ratioReturn per unit of downside risk | +2.33 | ||
| Omega ratioGain probability vs. loss probability | 1.54 | 1.18 | +0.37 |
| Calmar ratioReturn relative to maximum drawdown | 8.66 | 1.29 | +7.37 |
| Martin ratioReturn relative to average drawdown | 27.54 | 2.88 | +24.66 |
Loading charts...
Drawdowns
KLAC vs. ABBV - Drawdown Comparison
The maximum KLAC drawdown since its inception was -83.74%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for KLAC and ABBV.
Loading charts...
Drawdown Indicators
| KLAC | ABBV | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.74% | -45.09% | -38.65% |
Max Drawdown (1Y)Largest decline over 1 year | -22.41% | -17.32% | -5.09% |
Max Drawdown (3Y)Largest decline over 3 years | -34.95% | -20.74% | -14.21% |
Max Drawdown (5Y)Largest decline over 5 years | -40.28% | -21.92% | -18.36% |
Max Drawdown (10Y)Largest decline over 10 years | -40.28% | -45.09% | +4.81% |
Current DrawdownCurrent decline from peak | 0.00% | -4.60% | +4.60% |
Average DrawdownAverage peak-to-trough decline | -29.32% | -10.71% | -18.61% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.03% | 7.75% | -0.72% |
Volatility
KLAC vs. ABBV - Volatility Comparison
KLA Corporation (KLAC) has a higher volatility of 22.17% compared to AbbVie Inc. (ABBV) at 6.10%. This indicates that KLAC's price experiences larger fluctuations and is considered to be riskier than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| KLAC | ABBV | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 22.17% | 6.10% | +16.07% |
Volatility (6M)Calculated over the trailing 6-month period | 42.02% | 17.85% | +24.17% |
Volatility (1Y)Calculated over the trailing 1-year period | 49.38% | 24.31% | +25.07% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 43.88% | 22.89% | +20.99% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 41.86% | 25.73% | +16.13% |
Dividends
KLAC vs. ABBV - Dividend Comparison
KLAC's dividend yield for the trailing twelve months is around 0.31%, less than ABBV's 2.96% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ABBV AbbVie Inc. | 2.96% | 2.87% | 3.49% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% |
KLAC KLA Corporation | 0.31% | 0.61% | 0.96% | 0.92% | 1.25% | 0.91% | 1.35% | 1.74% | 3.17% | 2.15% | 2.67% | 2.94% |
Financials
KLAC vs. ABBV - Financials Comparison
This section allows you to compare key financial metrics between KLA Corporation and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
KLAC vs. ABBV - Profitability Comparison
KLAC - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, KLA Corporation reported a gross profit of 2.09B and revenue of 3.42B. Therefore, the gross margin over that period was 61.1%.
ABBV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported a gross profit of 12.53B and revenue of 15.00B. Therefore, the gross margin over that period was 83.5%.
KLAC - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, KLA Corporation reported an operating income of 1.41B and revenue of 3.42B, resulting in an operating margin of 41.2%.
ABBV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported an operating income of 4.73B and revenue of 15.00B, resulting in an operating margin of 31.6%.
KLAC - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, KLA Corporation reported a net income of 1.20B and revenue of 3.42B, resulting in a net margin of 35.2%.
ABBV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported a net income of 699.00M and revenue of 15.00B, resulting in a net margin of 4.7%.
Frequently Asked Questions
KLAC and ABBV have a correlation of -0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
KLAC has higher volatility (22.17%) compared to ABBV (6.10%). In terms of maximum drawdown, KLAC dropped -83.74% vs ABBV's -45.09%.
KLAC currently has the higher Sharpe Ratio (3.93 vs 0.92), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for KLAC and ABBV
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer